CardioMEMs HF System


Data Shows the CardioMEMS HF System Significantly Reduced 30-day Hospital Readmission Rates

A retrospective data analysis from the CHAMPION clinical trial showed significant reduction in 30-day hospital readmission rates for patients age 65 and older. It looked at the safety and effectiveness of the CardioMEMS™ HF System for patients with New York Heart Association (NYHA) Class III heart failure (HF) who had been hospitalized for HF in the previous 12 months.1

Read the News Release

The CardioMEMS™ HF System

CardioMEMS™ HF System

St. Jude Medical is proud to introduce a new tool for comprehensive heart failure care. The CardioMEMS™ HF System is the first and only FDA-approved heart failure (HF) monitor proven to significantly reduce HF hospital admissions and improve quality of life in NYHA class III patients.2

When used by clinicians to manage HF, the CardioMEMS HF System is:

  • Safe and reliable – 98.6% of patients were free from device or system complications1
  • Clinically proven – reduced HF admissions by 37%1
  • Proactive and personalized – patient management through direct monitoring of PA pressure and titration of medications


About St. Jude Medical

St. Jude Medical is a global medical device manufacturer dedicated to transforming the treatment of some of the world’s most expensive, epidemic diseases. The company does this by developing cost-effective medical technologies that save and improve lives of patients around the world. Headquartered in St. Paul, Minn., St. Jude Medical has four major clinical focus areas that include cardiac rhythm management, atrial fibrillation, cardiovascular and neuromodulation.



1 Adamson et al., Impact of Wireless Pulmonary Artery Pressure Monitoring on Heart Failure Hospitalizations and 30-Day Readmissions in Medicare-Eligible Patients with NYHA Class III Heart Failure: Results from the CHAMPION Trial AHA 2014, Chicago. Abstract 16744.
2 Abraham WT, Adamson PB, Bourge RC, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: A randomised controlled trial. Lancet. 2011;377(9766):658-66.